Aishi Corporation announces China's listing of tyrosine kinase inhibitor LeWeima ®

liver cancer is the world's second leading cause of cancer-related death, with statistics for 2012 showing that about 750,000 people died from the disease worldwide in the year, as well as about 780,000 new confirmed cases, about 80 percent of which occurred in Asiarecently, Aishi Announced that its China sub-
company(http://Weissa (China) Pharmaceutical Co., Ltdhas listed tyrosine kinase inhibitor Le Weima ® (generic name: methylene latinvatini)March 2018, Aishi and Mercado, in Fort Kenalworth, N.J., launched a strategic partnership for global joint development and joint commercialization of the ® of Lewema (Lunvastini) through a subsidiaryunder the agreement, the two companies will jointly develop and commercialize the ®, and the partnership between the two companies is taking place worldwideNext, Wesfarmers (China) Pharmaceuticalco Co., Ltdand Mercadon, the Chinese subsidiary of Mershadong Corporation in Kennarworth, N.J., will jointly promote the ® in Chinatoday, leWeima ® has been approved in more than 50 countries, including the United States, Japan, Europe for the treatment of refractory thyroid cancer, and in more than 45 countries, including the United States and Europe, approved with Ivemus for second-line treatment of renal cell carcinoma (RCC)In addition to China, leWeima ® has been approved in Japan, the United States, Europe, other Asian countries and other countries around the world for the treatment of hepatocellular carcinoma